Sagimet Biosciences Inc. (Series A) (SGMT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $10.43 (-2.89% 1D, market cap $735.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGMT ranks #837 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APMD (Apnimed Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $721.9M) and WVE (Wave Life Sciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $0 in revenue, -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 85% of 52W Range • RSI-14 at 53.2 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SGMT currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.93) and Max Pain ($10.95) forces dealer call-delta covering toward $12.02.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Sagimet Biosciences Inc. (Series A) (SGMT) dropped -2.89% to $10.43, trading at 85% of its 52-week range ($4.5 – $11.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regula
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announced that its strategic partner, Sagimet Biosciences Inc. ("Sagimet"), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal trial des
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal
SGMT pivots denifanstat to acne with Phase 3 data and a funded U.S. registrational trial.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SGMT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SGMT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Sagimet Biosciences Inc. (Series A) (SGMT) ranks #837 by composite RQD confidence (34/100, grade E) and #395 by equity capitalization ($735.7M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. APMD currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SGMT at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SGMT
ACTIVE
Sagimet Biosciences Inc. (Series A) | E | 34/100 | — | — | -35.0% | -2.89% | $735.7M | Benchmark Subject |
| APMD Apnimed Inc. | D | 47/100 | — | — | — | -9.45% | $721.9M | /apmd-vs-sgmt → |
| WVE Wave Life Sciences Inc. | E | 32/100 | — | — | -35.0% | -0.28% | $715.9M | /wve-vs-sgmt → |
| GYRE Gyre Therapeutics Inc. | D | 46/100 | 72.3x | 95.4% | 25.4% | -9.59% | $714.8M | /gyre-vs-sgmt → |
| ANNX Annexon Inc. | D- | 40/100 | — | — | -35.0% | -0.74% | $760.2M | /annx-vs-sgmt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sagimet Biosciences Inc. (Series A) (SGMT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$51.0M, operating cash flow of -$45.6M, and free cash flow of -$45.6M (-7.6% YoY). On the balance sheet, SGMT closed FY2025 with $116.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$51.0M | -$45.6M | -$45.6M | $116.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$45.6M | -$42.4M | -$42.4M | $160.3M | — |
| FY2023 (FY) | 2023-12-31 | $2.0M | -$27.9M | -$23.8M | -$23.8M | — | — |
As of 2026-11-01, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $10.43 (-2.89% 1D, market cap $735.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGMT ranks #837 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APMD (Apnimed Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $721.9M) and WVE (Wave Life Sciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $0 in revenue, -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SGMT last traded at $10.43 (-2.89% on volume of 746,467 shares), positioning the stock +5.04% above its 50-day simple moving average ($9.93) and +39.07% above its 200-day simple moving average ($7.50). Across its 52-week range of $4.50 to $11.45, SGMT sits at the 85.3% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.13 to $11.73).
Why SGMT Stock dropped -2.89% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).